Enabling Characterization of Protein Therapeutics Derived from Xpress CF™ Technology with LC-ESI UHR QTOF/MS

One of the significant analytical challenges for the biopharmaceutical industry is the comprehensive characterization of protein therapeutics over the course of drug development. This application note describes analytical platforms using liquid chromatography coupled with electrospray ultra-high resolution quadrupole time-of-flight mass spectrometry with enhanced dynamic range, high speed MS MS acquisition and high mass accuracy to characterize aglycosylated trastuzumab derived from Xpress CF™ technology.